Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2000-06-16
2002-11-26
McGarry, Sean (Department: 1635)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
C435S006120, C435S455000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
06485973
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to the control of prokaryotic multidrug susceptibility. More specifically, this invention relates to the use of oligonucleotides for the treatment of diseases, disorders, and conditions associated with drug resistance in bacteria.
Bacterial antibiotic and antimicrobial resistance has been recognized since the advent of antimicrobial agents. In the past, the appearance of resistant microorganisms has been addressed by the continued availability of effective alternative drugs. As reported by Neu (
Science
(1992) 257:1064-1073), the situation has recently changed dramatically, leading to increasing morbidity and mortality. The growing number of pathogens resistant to multiple, structurally unrelated drugs, and the fact that no new class of antimicrobials is likely to be introduced before the end of the decade, have been blamed for the present crisis of clinical and epidemiologic significance (see, e.g. Neu, supra). Thus, as discussed extensively in the medical and scientific literature, there is a growing need to formulate effective therapeutic approaches to counter the emergence of novel bacterial strains resistant to antibiotics.
Resistance to an antimicrobial agent may be an inherent property of the infecting organism, or may result from mutation or from transfer of an extrachromosomal genetic determinant, such as plasmids and transposons, followed by selection of resistant organisms. In recent years there has been increased interest in the role of chromosomal sequences involved in conferring antibiotic resistance. A novel chromosomal stress response locus, the multiple antibiotic resistance (mar) locus has been shown to control the expression of chromosomal genes involved in intrinsic multidrug susceptibility/resistance to multiple, structurally different antibiotics and other noxious agents in
Escherichia coli
and in other members of the
Enterobacteriaceae
family (Cohen et al. (1988)
J. Bacteriol
. 170:5416-5422; Cohen et al. (1993)
J. Infec. Dis
. 168:484-488).
The mar locus has been reported to include two transcriptional units, marC and marRAB. Each unit is divergently transcribed from a central regulatory region, marO (Cohen et al. (1993)
J. Bacteriol
. 175:1484-1492; and Goldman, J. et al. (1996)
Antimicrobiol. Agents Chemo
. 40:1266-1269). Both operons, marORAB and marC are necessary for the full expression of the Mar phenotype. Transcription of the marORAB operon is inducible two to three fold by tetracycline, chloramphenicol, salicylate, and other structurally unrelated compounds (Cohen et al., supra). Activated cells become resistant not only to multiple unrelated antibiotics but also to oxidative stress agents and organic solvents (Cohen et al., supra; George, et al. (1983)
J. Bacteriol
. 155:531-540; George et al. (1996)
FEMS Micro. Let
. 139:1-10).
In the presence of selective agents (e.g., tetracycline, chloramphenicol, nalidixic acid, rifampin, penicillin, and cephalosporin) Mar mutants arise spontaneously at a frequency of 10
−7
(George, et al.,
J. Bacteriol
. supra). Such mutants have been reported to favor the accumulation of secondary mutations leading to the expression of higher levels of resistance to novel or improved antimicrobial agents. For example, Mar mutants have recently been found among fluoroquinolone-resistant clinical isolates of
E. coli
(Maneewannakul et al.(996)
Antimicrob. Agents Chemo
. 38:542-546).
Characterization of several Mar mutant resistant strains has revealed constitutive transcription of mRNA from the marORAB operon as a result of various mutations within that operon (Cohen et al., supra). Consistent with these findings, the disruption of the mar locus has correlated with the complete loss of resistance. The resistance phenotype has been completely reversed to susceptibility by insertion of Tn5, a transposon element, into the marA gene of the
E. coli
chromosome. (George et al. (1983)
J. Bacteriol
. 155:541-548).
A promising new approach to antimicrobial therapy lies in the use of short synthetic strands of nucleic acids, called antisense oligonucleotides, to control gene expression. Inhibition of gene expression by antisense oligonucleotides relies at least in part, on the ability of the oligonucleotide to bind a complementary messenger RNA sequence, thereby preventing its translation (see generally, Agrawal (1992)
Trends in Biotech
. 10:152; Wagner et al.(1994)
Nature
372:333-335; and Stein et al. (1993)
Science
261:1004-1012). Synthetic oligonucleotides administered exogenously compose an alternate class of therapeutic agents and have been used successfully in both prokaryotic and eucaryotic systems.
Antisense oligonucleotides have been developed as antiparasitic agents, although none have been demonstrated to reverse the drug resistant phenotype of a drug resistant parasite strain. PCT publication No. WO 93/13740 discloses the use of antisense oligonucleotides directed to nucleic acids encoding the dihydrofolate reductase-thymidilate synthase gene of
P. falciparum
to inhibit propagation of drug-resistant malarial parasites. Rapaport et al. (
Proc. Natl. Acad Sci
. (
USA
) (1992) 89:8577-8580) teaches inhibition of the growth of chloroquine-resistant and chloroquine-sensitive
P. falciparum
in vitro using oligonucleotides directed to the dihydrofolate reductase-thymidylate synthase gene. PCT publication No. WO 94/12643 discloses antisense oligonucleotides directed to nucleic acids encoding a carbamoyl phosphate synthetase of
P. falciparum
. Tao et al. (
Antisense Res. Dev
. (1995) 5:123-129) teaches inhibition of propagation of a schistosome parasite by antisense oligonucleotides. Early experiments by Jayaraman showed that an antisense oligonucleotide complementary to the Shine-Delagarno ribosomal docking sequence of
E. coli
16S rRNA, inhibited translation of bacterial mRNA in cell-free extracts derived from
E. coli
(Jayaraman (1996)
Proc. Natl. Acad. Sci
(USA) 93:709-713). Furthermore, experiments were conducted by Gasparro et al. using a photoactivatable antisense DNA construct to suppress ampicillin resistance in
E. coli
(Gasparro et al.
Antisense Res. Dev
. (1991) 1:117-140). More recently, experiments utilizing antisense oligodeoxyribonucleotide phosphorothioates have shown the successful inhibition of the growth of a wild-type and drug resistant strain of
Mycobacterium smegmatis
(Rapaport et al. (1996)
Proc. Natl. Acad. Sci
. (USA) 93:709-713).
Bacteria have been known to mutate extensively, resulting in a large number of strains which have become resistant to most drugs presently available. In addition, new resistant bacterial strains are likely to develop as the time progresses. Thus, there is a continued need for development of additional therapeutic agents and effective methods to treat these bacterial infections. Inactivation or suppression of the multiple antibiotic resistance operon would ideally make some prokaryotes more susceptible to a larger number of antimicrobial agents and environmental stresses, thus providing novel means to counter increased bacterial resistance.
SUMMARY OF THE INVENTION
The invention disclosed herein satisfies this need. The present inventors have discovered that antisense oligonucleotides that are complementary to sequences found in the marORAB operon can inhibit or suppress the expression of one or more genes within that operon, thereby making bacteria more susceptible to a larger number of antimicrobial agents and environmental stresses.
This discovery has been exploited to develop the present invention which includes antisense oligonucleotides directed to mRNA derived from the marORAB operon sequences which specifically inhibit or suppress the expression of one or more genes within that operon, and which are therefore useful both as therapeutic agents and as tools to elucidate the role and biological significance of the marORAB operon sequences.
In one aspect, the invention provides a synthetic oligonucleotide complementary to a transcript of the marORAB operon which inhibits the expressi
Hofe Eric Von
Levy Stuart B.
Hanley, Esq. Elizabeth A.
Hybridon, Inc.
Lahive & Cockfield LLP
McGarry Sean
Williams, Esq. Megan E.
LandOfFree
Oligonucleotides specific for the marORAB operon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides specific for the marORAB operon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides specific for the marORAB operon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2992831